Healthcare Companies
Formation Bio launches $600m fund to buy and develop 10–15 drug programmes
Formation Bio, an AI-native pharmaceutical company, said its new Drug Development Accelerator Fund has $600m in capital commitments. It aims to acquire 10–15 programmes over three to five years.

Formation Bio, a New York-headquartered company that describes itself as an AI-native pharmaceutical company, announced the Formation Bio Drug Development Accelerator Fund on 28 October 2026. The fund has $600 million in capital commitments.
According to the company, the fund is designed to expand its portfolio of clinical-stage medicines. Formation Bio said it aims to acquire 10–15 drug programmes over the next three to five years and advance them through key clinical milestones.
How the fund is structured
The company said the fund's limited partners include research foundations, institutional endowments, hospitals and philanthropic organisations. Formation Bio is the fund's general partner through a wholly owned subsidiary and has committed its own capital alongside the limited partners. The fund finances only the acquisition and development of programmes within Formation Bio's portfolio.
Each funded programme sits in a standalone corporate entity, supported by Formation Bio's development organisation. The company said this keeps the economics of each asset financially distinct. It also said more capital can go to clinical development rather than to separate, duplicated operating infrastructure across several companies.
Chief executive and co-founder Benjamine Liu said the structure gives limited partners access to individual drug assets and, for the company, "creates paths to liquidity without selling the parent company". He also said it positions Formation Bio to lower its cost of capital over time. These are company claims and the release offers no supporting data.
Investment approach
Formation Bio said it acquires or in-licenses Phase 1 and Phase 2 programmes from pharmaceutical companies and biotechs, prioritising assets with a clear path to clinical proof of concept. It focuses on diseases with substantial unmet need but limited active development across the industry. It targets major clinical milestones within two to four years of acquisition, depending on the programme.
Capital will be deployed according to each programme's development needs. After meaningful clinical progress, the company expects to partner programmes with pharmaceutical companies for commercialisation or co-commercialisation.
Chief Business Officer David Steinberg said "promising medicines can get stranded in company pipelines" and described the fund as a new way to unlock their potential. Chief Scientific Officer and Head of R&D Michael Ehlers called the fund a next step in the real-world application of AI to drug development.
The release does not name the limited partners or any target programmes. Formation Bio is headquartered in New York City and has a second office in Boston.
Why it matters
The fund is an example of drug-asset financing in which each programme is held in its own entity under shared development infrastructure. Investors and corporate development teams could watch whether it delivers the cost-of-capital and liquidity benefits the company describes. Its plan to partner programmes with pharmaceutical companies after clinical progress suggests it may eventually become a source of mid-stage assets for larger groups. The release does not mention UK activity.
Source: PR Newswire – Health
Related stories


